Lantheus (LNTH) vs Neogen (NEOG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Neogen (NEOG) has outperformed Lantheus (LNTH) over the past year, gaining 108.9% versus a gain of 93.2%. Over five years, LNTH leads with a +330.7% price change compared with -71.5% for NEOG. Lantheus is the larger company by market cap ($6.54 billion vs $2.59 billion), about 2.5 times the size.
On valuation, Lantheus trades at a lower forward P/E (15.7x vs 31.3x for Neogen). Lantheus converts more of its revenue into profit, with a net margin of 15.2% versus -0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | NEOG |
|---|---|---|
| Share price | $100.16 | $11.89 |
| Market cap | $6.54B | $2.59B |
| 1-day change | -0.02% | +1.76% |
| YTD return | +50.53% | +67.10% |
| 1-year return | +93.25% | +108.94% |
| 5-year return | +330.70% | -71.54% |
| P/E ratio (TTM) | 24.25 | — |
| Forward P/E | 15.71 | 31.28 |
| EPS (TTM) | $4.13 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | $870.40M |
| Revenue growth (YoY) | +0.50% | -2.72% |
| Net income (latest FY) | $233.56M | $-7.90M |
| Gross margin | 61.10% | 46.93% |
| Operating margin | 20.16% | -2.48% |
| Net margin | 15.15% | -0.91% |
| 52-week high | $111.86 | $14.26 |
| 52-week low | $50.16 | $5.37 |
| Distance from 52-week high | -10.46% | -16.65% |
| Analyst consensus | none | buy |
| Avg. price target upside | +7.57% | +17.80% |
| Average volume | 1.32M | 3.02M |
| Shares outstanding | 65.30M | 218.11M |
| Employees | 1,193 | 2,636 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 2.5 times larger than Neogen by market value ($6.54B vs $2.59B).
- NEOG has outperformed LNTH by 15.7 percentage points over the past year.
- Lantheus is more profitable, keeping 15.2 cents of every revenue dollar as net income versus -0.9 cents for Neogen.
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
LNTH vs NEOG FAQ
Which is bigger, Lantheus or Neogen?
Lantheus (LNTH) is larger, with a market capitalization of $6.54B compared with $2.59B for Neogen (NEOG).
Which stock has performed better over the past year, LNTH or NEOG?
NEOG returned +108.94% over the past 12 months, compared with +93.25% for LNTH (price return, excluding dividends). Past performance does not predict future results.
Are Lantheus and Neogen in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.